The proportion of employers offering these medications tends to increase as employer increases in size as well, with KFFs data indicating that about 16% of employers that have between 200 and 999 employees offering semaglutide and/or other GLP-1 coverage for weight loss, while 24% of employers with between 1,000 and 4,999 employees cover these prescriptions, and 25% of employers that have 5,000 or more employees do so
patients, available in both open-claims and closed-claims versions
Twins with higher serum vitamin D concentrations had longer leukocyte telomere length
Diarrhea and constipation risk were doubled with semaglutide
When our body is lacking amino acids, it allows proteins to break down, leading to muscle loss and longer recovery times
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-Analysis